In Q4 of fiscal 2025, the quarter ended Dec 31, 2025, Vicarious Surgical Inc. used $9.3 million of cash from operations, up 21.0% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
Q2 FY2024
Jun 30, 2024
|
Q1 FY2024
Mar 31, 2024
|
|---|---|---|---|---|---|---|---|---|
| Operating | ||||||||
| Depreciation and amortization |
0
-46.3%
|
0
-30.6%
|
0
-23.1%
|
0
-29.2%
|
1
+3.2%
|
1
+13.4%
|
1
+21.8%
|
1
+18.1%
|
| Stock-based compensation |
1
-60.7%
|
2
-30.2%
|
2
-28.4%
|
3
-9.8%
|
3
-8.6%
|
3
-18.7%
|
3
-7.8%
|
3
-5.0%
|
| Operating cash flow |
-9
+21.0%
|
-10
+17.5%
|
-14
-22.8%
|
-12
+18.6%
|
-12
-3.7%
|
-13
+26.6%
|
-11
+26.9%
|
-14
+22.1%
|
| Investing | ||||||||
| Capital expenditures |
—
|
—
|
0
-100.0%
|
0
-50.0%
|
—
|
—
|
0
-97.1%
|
0
-96.7%
|
| Investing cash flow |
3
-79.1%
|
10
+2069.9%
|
15
+313.2%
|
5
+3303.5%
|
14
+186.4%
|
-0
+23.6%
|
-7
-9.4%
|
-0
+99.7%
|
| Financing | ||||||||
| Financing cash flow |
6
+94800.0%
|
0
|
0
|
0
+750.0%
|
0
-82.4%
|
0
-100.0%
|
0
-100.0%
|
0
-99.3%
|
| Change in cash | ||||||||
| Free cash flow |
—
|
—
|
-14
-22.7%
|
-12
+18.6%
|
—
|
—
|
-11
+27.9%
|
-14
+23.4%
|
| Per share | ||||||||
| Free cash flow per share |
—
|
—
|
-2.28
-21.4%
|
-1.99
+19.6%
|
—
|
—
|
-1.88
+48.0%
|
-2.47
-1550.6%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
- Listed as
- RBOT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1812173
- Former names
- D8 Holdings Corp. (until Sep 20, 2021)
Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
- Intuitive Surgical Inc ISRG
- Edwards Lifesciences Corp EW
- STERIS plc STE
- Zimmer Biomet Holdings, Inc. ZBH
- Smith & Nephew PLC SNN
- Align Technology Inc ALGN
- MSA Safety Inc MSA
- Establishment Labs Holdings Inc. ESTA
All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.